Biolevate raises $34.4M series a
Announced 22 September 2026
◆ The Round
Biolevate raised $34.4M in series a funding, announced on 22 September 2026, led by RAISE France, Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, EQT Ventures. The round is tracked live by Fusion42 as part of the Raise fund database and the Scout startup database.
◆ About Biolevate
Paris-based life sciences AI company providing an enterprise agentic AI platform for automating scientific and regulatory workflows in drug development. Biolevate is based in France and currently at series a stage, operating in Biotech, AI Infrastructure.
◆ Investors
LeadRAISE France, Orange Ventures
ParticipationMSD Global Health Innovation Fund, Station F, EQT Ventures
◆ Market context
This funding event is a citable node in Fusion42's market graph: it links Biolevate's Scout profile to the funds behind the round and to related Wire analysis, and is refreshed from public announcements as the round is confirmed or extended. It is the same live market data Arthur reasons over when benchmarking a founder's own raise against what is closing in the market right now.
◆ Explore the market
◆ FAQ
How much did Biolevate raise?
Biolevate raised $34.4M in its series-a round, announced 2026-09-22.
Who invested in Biolevate's series-a round?
The round was led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F and EQT Ventures.
What does Biolevate do?
Paris-based life sciences AI company providing an enterprise agentic AI platform for automating scientific and regulatory workflows in drug development.
Verified 22 September 2026 · Sources: public filings